NCT05815160 - Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2026

Conditions

Small Cell Lung Cancer Recurrent

Interventions

DRUG

Debio 0123

Administered as capsules.

DRUG

Etoposide

Administered as IV infusion.

DRUG

Carboplatin

Administered as IV infusion.

Trial Locations (15)

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

15006

RECRUITING

Hospital Universitario de A Coruna, A Coruña

28007

RECRUITING

Hospital General Universitario Gregorio Maranon, Madrid

28027

RECRUITING

Clinica Universidad de Navarra, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28050

RECRUITING

Hospital Universitario HM Sanchinarro. START Madrid - Centro Integral Oncológico Clara Campal (CIOCC), Madrid

28223

RECRUITING

NEXT Oncology Madrid, Madrid

29004

RECRUITING

Hospital Quironsalud Malaga, Málaga

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

46010

RECRUITING

Hospital Clinico Universitario de Valencia, Valencia

48202

WITHDRAWN

Henry Ford Health System, Detroit

72205

RECRUITING

University of Arkansas for Medical Sciences, Little Rock

08035

RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona

08036

RECRUITING

Hospital Clinic Barcelona, Barcelona

08908

RECRUITING

Institut Catala D'Oncologia - Badalona, Barcelona